You are here

Analysis of Cell Sense Labeled Human Cells

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI078602-01
Agency Tracking Number: AI078602
Amount: $273,009.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
603 STANWIX STREET SUITE 348
PITTSBURGH, PA 15222
United States
DUNS: 798793548
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 () -
Business Contact
Phone: (412) 263-2870
Email: info@celsense.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Cellular therapeutics represent great potential for curing and alleviating symptoms associated with debilitating human diseases, such as cancer, cardiovascular disease, and neurological disorders. Currently, no versatil
e methodology for tracking cellular products following administration exists, leading to delays in these therapies reaching the clinic. The ability to visualize the trafficking of transferred cells throughout the body non-invasively will give clinicians th
e ability to better understand why certain cellular transplants are successful and others are not. In addition, determining the biodistribution of transferred cells is of paramount importance to overcome government regulatory hurdles for these therapies. I
n this study, we propose characterizing a novel fluorochemical cell tracking reagent recently created for use with MRI, called Cell Sense. This product is an emulsion of fluorine-containing nanoparticles that is used to label cells in culture and enables t
ransferred cells to be visualized with great specificity in vivo using 19F MRI. Cell Sense has been tested extensively in mouse cells and imaged using in vivo rodent models. It has not yet been tested on clinically relevant human cells. In this proposal, w
e will examine the Cell Sense labeling characteristics in a variety of primary human immune cell types, including dendritic cells, natural killer cells, and T cells, that are currently being used in immunotherapeutic trials. Also, stem cells, including hum
an neural progenitor cells (hNPC) and CD34+ cell types, will be studied. This proposal has two Specific Aims: (1) to develop ex vivo cell labeling protocols and examine the Cell Sense labeling dose in therapeutically relevant human cells; and (2) to determ
ine whether the fluorochemical labeling has any detrimental impact on human cell viability or normal function. To achieve these Aims, we will employ an extensive battery of in vitro assays to assess cell loading, cytotoxicity, proliferation, phenotype, and
function. Combining these results, we will be able to devise optimal labeling protocols for a diverse range of cell types that are currently being used for human clinical trials. By establishing Cell Sense's ability to label a wide variety of human cells
with limited toxicity, we will have achieved a critical milestone in moving closer toward a clinical-grade product that can be used to track current transplanted cells for therapeutic use. We believe that the potential impact of Cell Sense is significant,
by removing many of the scientific and regulatory hurdles that developers of cellular therapeutics for the clinic currently face. PUBLIC HEALTH RELEVANCE: Understanding how therapeutically relevant cell types behave following adoptive transfer or transplan
tation may help us develop novel therapies. This project examines the use of novel fluorochemical MRI reagents to image and detect labeled, transplanted cells non-invasively. The results of this study will move MRI cell tracking closer to clinical adoption
and will provide researchers and physicians the opportunity to selectively follow labeled cells following administration.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government